What Endogene does

Endogene Ltd. is an Australian unlisted public medical device developer, headquartered in Brighton, Victoria, founded in 2008 and operating with 1–10 employees. The company incubates and develops proprietary technologies for gastrointestinal endoscopy and vascular surgery, with the stated intent to commercialise via licensing or manufacturing partnerships on a global or regional basis. Its go-to-market is sales-led, targeting gastroenterologists, cardiovascular and thoracic surgeons, bariatric surgeons, and general surgeons, with current website information restricted on a terms-of-use basis to medical practitioners resident in Australia.

Endogene's core product portfolio centres on two proprietary platforms. The first is the Parascope, a single-use self-propelling endoscope built on the company's Fluid Kinetic Propulsion (FKP) technology, which transfers kinetic energy through a sealed fluid column inside the endoscope to drive forward movement without mechanical pushing, enabling examination of the entire gastrointestinal tract with one device and eliminating the need for separate gastroscopes, enteroscopes, and colonoscopes. A portable video processor and drive unit completes the system for clinic and field use. The second platform is the Linear Vascular Anastomosis System (L-VAS), a fixation system for vascular grafts that uses shape memory alloy ring staples delivered via a dedicated instrument, enabling transmural fixation with only endoluminal access for coronary bypass, aortic aneurysm repair, valve surgery, and transplant applications. Supporting products include gastrointestinal surgical clips and a gall stone removal instrument.

The business model combines intended hardware sales of single-use disposable devices with potential licensing, royalty, and international manufacturing partnership revenue. Pricing is not publicly disclosed, the company is pre-commercialisation, and funding to date has come from private investors supplemented by an Australian Biotechnology Innovation Fund grant, an Australian Export Market Development grant, and R&D tax concession funds. Endogene develops its devices under an ISO 13485:2016 quality system and is a member of the Australian Association for Quality.

Name

Endogene

Legal name

Endogene Ltd.

Website

https://endogene.com.au

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Endogene Ltd. is an Australian pre-commercialisation medical device developer creating proprietary self-propelling endoscopes (Parascope, Fluid Kinetic Propulsion) and shape memory alloy vascular graft fixation systems (L-VAS) for gastroenterologists and cardiovascular surgeons, with plans to monetise via global licensing and manufacturing partnerships.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)

akta.pro secondary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Endoscopic medical devices
• Vascular anastomosis systems
• Self-propelling endoscopes
• Surgical instruments
• Minimally invasive devices

Headquarters

HQ city

Brighton

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Sales: Endogene generates revenue through the sale of medical devices including the Parascope self-propelling endoscope and Linear Vascular Anastomosis System. The devices are described as being manufactured as single-use, disposable units.
2. Licensing and Partnerships: The company's commercialisation strategy includes potential for entering into commercial partnering or licensing arrangements for its technologies on a global or regional basis, and establishing international manufacturing partnerships.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Endogene is a medical device company developing proprietary technologies for gastrointestinal endoscopy and vascular surgery. Its core offerings include the Parascope self-propelling endoscope (using Fluid Kinetic Propulsion) for total GI tract examination and intervention, and the Linear Vascular Anastomosis System (L-VAS) using shape memory alloy ring staples for secure vascular graft fixation in open and minimally invasive procedures. Supporting endoscopic instruments include surgical clips and a gall stone removal instrument.

Product overview

Endogene is a medical technology company developing proprietary devices for gastrointestinal endoscopy and vascular surgery. The core product portfolio consists of the Parascope® self-advancing endoscope (powered by Fluid Kinetic Propulsion technology) and the Linear Vascular Anastomosis System (L-VAS) for vascular graft fixation. The company also develops supporting endoscopic instruments including surgical clips and gall stone removal tools. Endogene is developing both reusable and single-use disposable versions of its Parascope® product.

Differentiator

Problem solved

Functional benefit

Brands

• Parascope: Single-use, self-propelling endoscope powered by Fluid Kinetic Propulsion technology for total gastrointestinal tract endoscopy and interventions.
• Linear Vascular Anastomosis System (L-VAS)
• Fluid Kinetic Propulsion (FKP)

Products and services

• Parascope Single-use, self-propelling endoscope using Fluid Kinetic Propulsion (FKP) technology for total gastrointestinal tract endoscopy and interventions. Enables clinicians to examine and treat the entire intestine with one device, eliminating the need for mechanical pushing and reducing cross-infection risk. Available as both reusable and single-use devices. Targeted at gastroenterologists and gastrointestinal surgeons in Australia and globally.
• Linear Vascular Anastomosis System (L-VAS) Shape memory alloy-based fixation system for vascular grafts enabling fast, secure tissue connection during minimally invasive procedures, including endoscopic and open heart bypass surgeries. Delivers multiple ring staples simultaneously to avoid graft trauma and reduce the risk of stenosis at graft-vessel junctions. Achieves transmural fixation with only endoluminal access. Targeted at cardiovascular and thoracic surgeons performing coronary artery bypass grafts, aortic aneurysm repair, heart valve replacement, and vascular anastomosis in transplant surgery.
• Surgical Clips Gastrointestinal surgery clips designed for use in surgical procedures requiring tissue ligation or fixation. Targeted at surgeons performing gastrointestinal surgical interventions.
• Gall Stone Removal Instrument Endoscopic instrument specifically designed for gall stone removal procedures. Targeted at gastroenterologists and general surgeons performing minimally invasive biliary interventions.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor.

• GI DynamicsminorOthersAnthony Switzer, Head of Technology Development at Endogene, previously served as Head of The Australian Business Unit of GI Dynamics, a manufacturer of novel, endoscopically-delivered implants for the treatment of diabetes and obesity. This is a personnel relationship rather than a formal company partnership.
• Smith & Nephew SurgicalminorOthersAnthony Switzer spent nearly 15 years with Smith & Nephew Surgical before joining GI Dynamics and later Endogene. This is a historical personnel relationship rather than a formal company partnership.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Getinge AB: Major surgical and vascular surgery device manufacturer with anastomosis, grafting and cardiac surgery product lines. Adjacent incumbent comparable to Endogene's L-VAS application areas.
• Pentax Medical (Hoya Corporation): Established flexible endoscopy manufacturer with GI, ENT and urology endoscope systems. Competes with Endogene in the GI endoscope market with deep hospital installed-base relationships.
• Boston Scientific Corporation: Has entered single-use endoscopy with the EXALT platform (acquired via acquisition of Spiration and others) and competes in adjacent GI therapeutic device categories where Endogene's surgical clips and gall stone removal instrument operate.
• Fujifilm Healthcare: Major endoscopy incumbent with a broad GI endoscopy portfolio and growing presence in single-use visualization. Directly competes with Endogene in the gastroenterology endoscope category.
• Olympus Corporation: Dominant global incumbent in flexible endoscopy with the largest installed base of GI endoscopes worldwide and a comprehensive single-use endoscopy portfolio. Directly competes with Endogene's Parascope in the gastroenterology endoscope market.
• LivaNova PLC: Cardiac surgery company offering products for CABG and heart valve procedures, including anastomosis devices. Most directly comparable to Endogene's L-VAS vascular anastomosis system in the cardiac surgery space.

Emerging players

• CapsoVision, Inc. Developer of the CapsoCam capsule endoscope for small-bowel visualization — a competing modality to overcome the limitations of push endoscopes in reaching the entire small intestine, addressing the same clinical problem Parascope targets.
• Artivion, Inc. Specialty cardiac and vascular surgery company (formerly CryoLife) focused on aortic repair, heart valves and vascular grafts. Comparable to Endogene's L-VAS in surgical vascular anastomosis and grafting.
• AnX Robotica: Developer of the NaviCam capsule endoscopy system for GI visualization. Represents an alternative technology approach to overcoming limitations of push endoscopes — the same unmet need Endogene's FKP-based Parascope addresses.

Direct peers

• Ambu A/S: Global leader in single-use endoscopy with the aScope platform across bronchoscopy, cystoscopy and GI. Closest direct competitor to Endogene's Parascope single-use endoscope strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/endogene-ltd-/about

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endogene